Abstract
The incidence of prostate cancer continues to increase in the US. Compared with other common cancers such as those of the breast and lung, the causes of prostate cancer remain poorly understood. Research endeavors continue to identify predictors of risk for prostate cancer, of which familial and genetic factors are among the strongest. Known risk factors can show significant heterogeneity in their association with prostate cancer development. However, the identification and further characterization of risk modifiers might provide insight into treatment and prevention of prostate cancer.
Key Points
-
Prostate cancer remains the most common noncutaneous cancer in men worldwide
-
Risk factors for prostate cancer are numerous and heterogeneous; they include genetic, inflammatory and infectious, androgen-related, dietary, age-related, and ethnic factors that contribute to prostate cancer susceptibility
-
Numerous research endeavors are underway to identify and characterize factors that modify the risk of prostate cancer
-
Modifiable risk factors, once discovered, can be targeted in prostate cancer prevention strategies
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Coleman MP et al. (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9: 730–756
Nelen V (2007) Epidemiology of prostate cancer. Recent Results Cancer Res 175: 1–8
Grönberg H (2003) Prostate cancer epidemiology. Lancet 361: 859–864
Sakr WA et al. (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379–385
Hankey BF et al. (1999) Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91: 1017–1024
Potosky AL et al. (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548–552
Lilja H et al. (2007) Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 25: 431–436
Quinn M and Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 90: 174–184
Woolf CM (1960) An investigation of the familial aspects of carcinoma of the prostate. Cancer 13: 739–744
Eeles RA et al. (1997) Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol 79 (Suppl 1): 8–14
Bratt O (2002) Hereditary prostate cancer: clinical aspects. J Urol 168: 906–913
Carter BS et al. (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150: 797–802
Carter BS et al. (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89: 3367–3371
Grönberg H et al. (1994) Studies of genetic factors in prostate cancer in a twin population. J Urol 152: 1484–1487
Page WF et al. (1997) Heredity and prostate cancer: a study of World War II veteran twins. Prostate 33: 240–245
Gillanders EM et al. (2004) Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 96: 1240–1247
Klein EA and Silverman R (2008) Inflammation, infection, and prostate cancer. Curr Opin Urol 18: 315–319
Amundadottir LT et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38: 652–658
Zheng SL et al. (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358: 910–919
Xu J et al. (2008) Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 14: 5819–5824
Ellinger J et al. (2008) CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71: 161–167
Petrovics G et al. (2005) Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24: 3847–3852
Oikawa T and Yamada T (2003) Molecular biology of the ETS family of transcription factors. Gene 303: 11–34
Tomlins SA et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648
Perner S et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337–8341
Morris DS et al. (2008) The discovery and application of gene fusions in prostate cancer. BJU Int 102: 276–282
Coussens LM and Werb Z (2002) Inflammation and cancer. Nature 420: 860–867
Platz EA and De Marzo AM (2004) Epidemiology of inflammation and prostate cancer. J Urol 171 (2 Suppl): S36–S40
Dennis LK et al. (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60: 78–83
Dennis LK and Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13: 72–79
Sarma AV et al. (2006) Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J Urol 176: 1108–1113
Sutcliffe S et al. (2006) Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2160–2166
Sutcliffe S et al. (2007) Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 16: 1573–1580
De Marzo AM et al. (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256–269
Casey G et al. (2002) RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32: 581–583
Larson BT et al. (2008) Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J Urol 179: 1344–1348
Urisman A et al. (2006) Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2: e25
Hsing AW (2001) Hormones and prostate cancer: what's next? Epidemiol Rev 23: 42–58
Gann PH et al. (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118–1126
Eaton NE et al. (1999) Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80: 930–934
Roddam AW et al. (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100: 170–183
Jaffe JM et al. (2000) Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 60: 1626–1630
Makridakis NM et al. (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354: 975–978
Pearce CL et al. (2008) No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Hum Mol Genet 17: 2456–2461
Scariano JK et al. (2008) The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer. Prostate 68: 1798–1805
Setiawan VW et al. (2007) CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 16: 2237–2246
Sarma AV et al. (2008) Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate 68: 296–305
Neslund-Dudas C et al. (2007) SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate 67: 1654–1663
Thompson IM et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215–224
Lucia MS et al. (2007) Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99: 1375–1383
Redman MW et al. (2008) Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila Pa) 1: 174–181
Bostwick DG et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371–2490
Muir CS et al. (1991) The epidemiology of prostatic cancer: geographical distribution and time-trends. Acta Oncol 30: 133–140
Shimizu H et al. (1991) Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63: 963–966
Kaaks R et al. (2000) Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic Dis 3: 157–172
Nelson WG et al. (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172 (5 Suppl): S6–S11
Clinton SK et al. (1988) The combined effects of dietary protein and fat intake during the promotion phase of 7,12-dimethylbenz(a)anthracene-induced breast cancer in rats. J Nutr 118: 1577–1585
Wang Y et al. (1995) Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 87: 1456–1462
Aronson WJ et al. (1999) Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer 35: 130–136
MacInnis RJ and English DR (2006) Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 17: 989–1003
Gong Z et al. (2006) Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 15: 1977–1983
Han JH et al. (2008) Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men. Urology 72: 749–754
Freedland S et al. (2008) Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 72: 1102–1105
Kasper JS and Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2056–2062
Leitzmann MF et al. (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19: 1267–1276
Frankenberry KA et al. (2004) Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 188: 560–565
Somasundar P et al. (2004) Leptin is a growth factor in cancer. J Surg Res 116: 337–349
Hsing AW et al. (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86: 843S–857S
Ribeiro R et al. (2004) Overexpressing leptin genetic polymorphism (–2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59: 268–274
Giovannucci E et al. (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85: 1571–1579
Hayes RB et al. (1999) Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8: 25–34
Oakley-Girvan I et al. (2004) Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev 13: 1325–1330
Lippman SM et al. (2005) Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97: 94–102
Lippman SM et al. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39–51
Sesso HD et al. (2001) Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. Int J Epidemiol 30: 749–755
Schoonen WM et al. (2005) Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer 113: 133–140
Ewings P and Bowie C (1996) A case–control study of cancer of the prostate in Somerset and east Devon. Br J Cancer 74: 661–666
Giles GG et al. (2003) Sexual factors and prostate cancer. BJU Int 92: 211–216
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Patel, A., Klein, E. Risk factors for prostate cancer. Nat Rev Urol 6, 87–95 (2009). https://doi.org/10.1038/ncpuro1290
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1290
This article is cited by
-
Proteomics of prostate cancer serum and plasma using low and high throughput approaches
Clinical Proteomics (2024)
-
Systemic lupus erythematosus and prostate cancer risk: a pool of cohort studies and Mendelian randomization analysis
Journal of Cancer Research and Clinical Oncology (2023)
-
Recently Top Trending Cancers in a Tertiary Cancer Hospital in Pakistan
Dr. Sulaiman Al Habib Medical Journal (2023)
-
Exploring the role of the inflammasomes on prostate cancer: Interplay with obesity
Reviews in Endocrine and Metabolic Disorders (2023)
-
Unravelling genetic variants of a swedish family with high risk of prostate cancer
Hereditary Cancer in Clinical Practice (2022)